Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats

Journal of Molecular Medicine

Volumn 85, Issue 5, 2007, Pages 523-530

  D'Argenio, Giuseppe ^a   Petrosino, Stefania ^b,c   Gianfrani, Carmen ^d   Valenti, Marta ^b   Scaglione, Giuseppe ^e   Grandone, Ilenia ^a   Nigam, Santosh ^f   Sorrentini, Italo ^e   Mazzarella, Giuseppe ^d   Di Marzo, Vincenzo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d CNR   (Italy)

^e Gastroenterologia   (Italy)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Atrophy; Cannabinoid; Celiac disease; Endocannabinoid; Intestinal inflammation

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ANTIBODY; BIOLOGICAL MARKER; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; METHOTREXATE; PALMIDROL;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; ATROPHY; CELIAC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DUODENUM MUCOSA; ENTERITIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE; MALE; SCHOOL CHILD; UPREGULATION;

ADOLESCENT; ADULT; ANIMALS; ARACHIDONIC ACIDS; ATROPHY; CASE-CONTROL STUDIES; CELIAC DISEASE; CHILD; DIET, PROTEIN-RESTRICTED; DISEASE MODELS, ANIMAL; DUODENUM; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HUMANS; JEJUNUM; MALE; METHOTREXATE; MIDDLE AGED; PALMITIC ACIDS; PEROXIDASE; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TIME FACTORS; UP-REGULATION;

EID: 34247859056     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0192-3     Document Type: Article

References (34)

1. Maki M, Collin P (1997) Coeliac disease. Lancet 349:1755-1759
2. Corazza GR, Gasbarrini G (1995) Coeliac disease in adults. Baillieres Clin Gastroenterol 9:329-350
3. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3:797-801
4. Murray JA (1999) The widening spectrum of celiac disease. Am J Clin Nutr 69:354-365
5. Catassi C, Ratsch IM, Fabiani E, Rossini M, Bordicchia F, Candela F, Coppa GV, Giorgi PL (1994) Coeliac disease in the year 2000: exploring the iceberg. Lancet 343:200-203
6. Molberg O, McAdam SN, Sollid LM (2000) Role of tissue transglutaminase in celiac disease. J Pediatr Gastroenterol Nutr 30:232-240
7. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094-1104
8. Taminiau JA, Gall DG, Hamilton JR (1980) Response of the rat small-intestine epithelium to methotrexate. Gut 21:486-492
9. Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC (1996) Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 126:2519-2530
10. D'Argenio G, Sorrentini I, Ciacci C, Spagnuolo S, Ventriglia R, de Chiara A, Mazzacca G (1989) Human serum transglutaminase and coeliac disease: correlation between serum and mucosal activity in an experimental model of rat small bowel enteropathy. Gut 30:950-954
11. Izzo AA, Coutts AA (2005) Cannabinoids and the digestive tract. Handb Exp Pharmacol 168:573-598
12. Massa F, Monory K (2006) Endocannabinoids and the gastrointestinal tract. J Endocrinol Investig 29:47-57
13. Hornby PJ, Prouty SM (2004) Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 141:1335-1345
14. Di Marzo V, Izzo AA (2006) Endocannabinoid overactivity and intestinal inflammation. Gut 55:1373-1376
15. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V (2006) Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20:568-570
16. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202-1209
17. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'Argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V (2003) Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125:677-687
18. Marsh MN (1992) Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiological approach to the spectrum of gluten sensitivity. Gastroenterology 102: 330-354
19. Senger S, Maurano F, Mazzeo MF, Gaita M, Fierro O, David CS, Troncone R, Auricchio S, Siciliano RA, Rossi M (2005) Identification of immunodominant epitopes of alpha-gliadin in HLA-DQ8 transgenic mice following oral immunization. J Immunol 175:8087-8095
20. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534
21. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S (2005) Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129:437-453
22. D'Argenio G, Ciacci C, Sorrentini I, Ventriglia R, Spagnuolo S, Mattera D, Mellone MC, Iovino P, Mazzacca G (1988) Transglutaminase activity along the rat small bowel and cellular location. Enzyme 39:227-230
23. Guagnini F, Valenti M, Mukenge S, Matias I, Bianchetti A, Di Palo S, Ferla G, Di Marzo V, Croci T (2006) Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 55:946-953
24. Gianfrani C, Levings MK, Sartirana C, Mazzarella G, Barba G, Zanzi D, Camarca A, Iaquinto G, Giardullo N, Auricchio S, Troncone R, Roncarolo MG (2006) Gliadin-specific type-1 regulatory T cells from intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol 177:4178-4186
25. Klein TW, Newton C, Larsen K, Chou J, Perkins I, Lu L, Nong L, Friedman H (2004) Cannabinoid receptors and T helper cells. J Neuroimmunol 147:91-94
26. Usai P, Usai Satta P, Lai M, Corda MG, Piras E, Calcara C, Boy MF, Morelli A, Balestrieri A, Bassotti G (1997) Autonomic dysfunction and upper digestive functional disorders in untreated adult coeliac disease. Eur J Clin Invest 27:1009-1015
27. Massa F, Storr M, Lutz B (2005) The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 83:944-954
28. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. (2002) Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448:410-422
29. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, Esposito G, Mascolo N, Di Marzo V, Capasso F (2001) Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134:563-570
30. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. (2006) Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291:G364-G371
31. Re G, Barbero R, Miolo A, Di Marzo V (2007) Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Vet J 173:23-32
32. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15-19
33. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N, Di Marzo V (2001) Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 134:945-950
34. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, Sorrentini I, Di Marzo V (2005) Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available preclinical data, and first human studies. Neuropharmacology 48:1154-1163